Literature DB >> 17355107

Adjuvant hypofractionated radiation therapy for breast cancer after conserving surgery.

L Livi1, M Stefanacci, S Scoccianti, D Dicosmo, S Borghesi, F Nosi, G Simontacchi, M Mangoni, F Paiar, P Ponticelli, J Nori, A Chiavacci, G P Biti.   

Abstract

AIMS: To evaluate the incidence of locoregional recurrence (LRR) and the cosmetic results in a group of patients with breast cancer treated with a hypofractionated schedule of adjuvant radiotherapy after conservative surgery.
MATERIALS AND METHODS: In total, 539 patients with pTis-pT1-pT2 breast cancer underwent radiotherapy treatment after conservative surgery at the University of Florence and at the Pistoia Hospital. The dose delivered was 44 Gy (2.75 Gy daily fraction). The tumour bed boost (10 Gy) was given by electrons.
RESULTS: At the time of the analysis, 1.8% of patients (10/539) had breast relapse. No patients developed nodal recurrence (supraclavicular, axillary and internal mammary nodes). The 3- and 5-year actuarial rates for LRR were 1.2% (+/- 0.5% standard error) and 2.1% (+/- 0.6% standard error), respectively. Considering the late toxicity, we found that 412 (76.4%) patients had grade 0 or grade 1 late toxicity, 113 patients (20.9%) had grade 2 late toxicity and 14 patients (2.5%) had grade 3 late toxicity. No patients developed grade 4 toxicity.
CONCLUSION: This type of approach resulted in an effective treatment in terms of local control in patients with negative or one to three positive axillary nodes and negative surgical margins. Patients treated with a hypofractionated schedule showed very good cosmesis.

Entities:  

Mesh:

Year:  2007        PMID: 17355107     DOI: 10.1016/j.clon.2006.11.006

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  5 in total

1.  Assessment of contralateral mammary gland dose in the treatment of breast cancer using accelerated hypofractionated radiotherapy.

Authors:  Maria Tolia; Kalliopi Platoni; Andreas Foteineas; Maria-Aggeliki Kalogeridi; Anna Zygogianni; Nikolaos Tsoukalas; Mariangela Caimi; Niki Margari; Maria Dilvoi; Panagiotis Pantelakos; John Kouvaris; Vassilis Kouloulias
Journal:  World J Radiol       Date:  2011-09-28

2.  Hypofractionated radiotherapy in the treatment of early breast cancer.

Authors:  George Plataniotis
Journal:  World J Radiol       Date:  2010-06-28

3.  Hypo- vs. normofractionated radiation therapy in breast cancer: A patterns of care analysis in German speaking countries.

Authors:  M Mayinger; C Straube; D Habermehl; M N Duma; S E Combs
Journal:  Rep Pract Oncol Radiother       Date:  2020-07-28

4.  A biologically competitive 21 days hypofractionation scheme with weekly concomitant boost in breast cancer radiotherapy feasibility acute sub-acute and short term late effects.

Authors:  Marina Guenzi; Stefano Vagge; Ngwa Che Azinwi; Alessia D'Alonzo; Liliana Belgioia; Stefania Garelli; Marco Gusinu; Renzo Corvò
Journal:  Radiat Oncol       Date:  2010-11-22       Impact factor: 3.481

5.  Radiotherapy after conservative surgery in ductal carcinoma in situ of the breast: a review.

Authors:  Maurizio Amichetti; Cristiana Vidali
Journal:  Int J Surg Oncol       Date:  2012-05-13
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.